Vote Scores

Home / Companies / Stoke Therapeutics, Inc. / 3 Jun 2026

Meeting · year to 30 June 2026323 filers reporting

Stoke Therapeutics, Inc.: meeting of 3 Jun 2026

Votes reported on Form N-PX, item by item

323 Form N-PX filers reported votes at the Stoke Therapeutics, Inc. meeting of 3 Jun 2026. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

3 nominees; 73.1% of reported votes for; 76 filers withheld from or voted against at least one nominee.

708 vote records from 124 filers. 14 of the 123 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

88.7% for0.0% against11.3% other11.4% against management124 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

496 vote records from 322 filers. 144 of the 305 filers that marked the item either way voted against management. 17 filers reported this item without a management mark.

48.4% for44.7% against6.8% other47.2% against management322 filers68.1% for31.8% against0.2% other31.8% against management66,388,393 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

236 vote records from 124 filers. 2 of the 123 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

97.6% for0.8% against1.6% other1.6% against management124 filers99.5% for0.5% against0.1% other0.5% against management17,404,938 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForForFor
BlackRock and iSharesForForFor
FidelityAbstain or withhold *Against *For
DimensionalAbstain or withhold *Against *For
State Street and SPDRForAgainst *For
American CenturyForAgainst *For
Franklin TempletonForAgainst *For
InvescoForAgainst *For
EquitableForForFor
Charles SchwabForForFor
Nuveen and TIAAForForFor
ProShares and ProFundsForAgainst *For
John Hancock and ManulifeForAgainst *For
Morgan Stanley, Eaton Vance and CalvertForAgainst *For
J.P. MorganForForFor
Goldman SachsForForFor
WisdomTreeForForFor
PGIM and PrudentialAbstain or withhold *ForFor
Jackson National fundsForAgainst *For
Northern Trust and FlexSharesForAgainst *For
SEIForForFor
T. Rowe PriceForForFor
Lincoln FinancialForAgainstFor
VoyaForForFor
First TrustForAgainstFor
Russell InvestmentsNo reportForNo report
NationwideForForFor
Victory CapitalForAgainst *For
Brighthouse FundsForForFor
Guggenheim and RydexForAgainst *For
Columbia ThreadneedleForAgainst *For
BNY MellonNo reportForNo report
PrincipalForAgainst *For
Pacific Life fundsForForFor
Global XForForFor
MFSForForFor
TransamericaForForFor
Federated HermesForForFor
AllianceBernsteinNo reportAgainst *No report
Hartford FundsForForFor
DWSForAgainst *For
AllspringForAgainst *For
Harbor FundsForForFor
Janus HendersonNo reportAgainst *No report
Neuberger BermanNo reportForNo report
Artisan PartnersNo reportAgainst *No report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Stoke Therapeutics, Inc. meeting?

323 Form N-PX filers reported votes at the meeting of 3 Jun 2026. On say-on-pay, 144 of 305 voted against management (47.2%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Stoke Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Stoke Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Stoke Therapeutics, Inc. with a meeting date within three days of 3 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.